Free Trial

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

Alnylam Pharmaceuticals logo
$465.89 -2.69 (-0.57%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$470.00 +4.11 (+0.88%)
As of 09/12/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
4
Buy
23

Based on 27 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 4 have given a hold rating, and 23 have given a buy rating for ALNY.

Consensus Price Target

$421.28
-9.57% Downside
According to the 27 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $421.28. The highest price target for ALNY is $583.00, while the lowest price target for ALNY is $220.00. The average price target represents a forecasted downside of -9.57% from the current price of $465.89.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ALNY Analyst Ratings Over Time

TypeCurrent Forecast
9/13/24 to 9/13/25
1 Month Ago
8/14/24 to 8/14/25
3 Months Ago
6/15/24 to 6/15/25
1 Year Ago
9/14/23 to 9/13/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
23 Buy rating(s)
23 Buy rating(s)
21 Buy rating(s)
17 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$421.28$403.92$319.58$279.14
Forecasted Upside-9.57% Downside-8.77% Downside3.76% Upside5.23% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alnylam Pharmaceuticals Stock vs. The Competition

TypeAlnylam PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-9.57% Downside17,449.73% Upside10.73% Upside
News Sentiment Rating
Positive News

See Recent ALNY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/11/2025Evercore ISI
3 of 5 stars
Liisa Bayko
Liisa Bayko
Not Rated
Boost TargetOutperform$280.00 ➝ $515.05+9.93%
9/5/2025BMO Capital Markets
4 of 5 stars
Boost TargetOutperform$450.00 ➝ $470.00+3.66%
9/2/2025HC Wainwright
1 of 5 stars
Reiterated RatingBuy$570.00+27.55%
9/2/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$527.00 ➝ $583.00+29.48%
8/6/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$348.00 ➝ $475.00+10.95%
8/4/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeMarket PerformOutperform$490.00+21.95%
8/4/2025Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeUnderperformPeer Perform
8/1/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetSector Outperform$342.00 ➝ $450.00+12.00%
8/1/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$403.00 ➝ $550.00+38.02%
8/1/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$390.00 ➝ $415.00+4.88%
8/1/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$333.00 ➝ $395.00-0.23%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$329.00 ➝ $460.00+17.28%
8/1/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$304.00 ➝ $449.00+14.47%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetEqual Weight$312.00 ➝ $405.00+3.25%
8/1/2025Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$325.00 ➝ $400.00+1.98%
7/31/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$377.00 ➝ $478.00+21.63%
7/30/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$370.00+11.93%
7/21/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$385.00+20.11%
7/11/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$336.00 ➝ $359.00+11.27%
7/7/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$328.00 ➝ $384.00+18.58%
3/31/2025Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$353.00+31.49%
3/31/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$300.00 ➝ $345.00+28.51%
3/21/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$310.00 ➝ $330.00+17.29%
3/21/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
1/7/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$314.00 ➝ $310.00+31.53%
10/21/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$282.00 ➝ $371.00+25.37%
10/11/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$220.00 ➝ $220.00-21.77%
8/16/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$198.00 ➝ $370.00+40.85%
6/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetMarket Perform$138.00 ➝ $159.00-33.15%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:36 AM ET.


Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 9, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

  • Alnylam Pharmaceuticals, Inc. has received a reaffirmed "Buy" rating from HC Wainwright, indicating strong confidence in the company's future performance.
  • The current stock price is around $452, which reflects a significant increase from its twelve-month low, suggesting positive market sentiment.
  • Analysts have set a target price of $570, indicating potential for substantial upside from the current trading levels.
  • The company has a robust pipeline with projected earnings growth, with estimates showing earnings per share increasing significantly in the coming years.
  • Insider trading activity shows that executives are actively managing their holdings, which can be a positive signal about the company's prospects.

Alnylam Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

  • The company has a high debt-to-equity ratio, which may indicate financial risk and could affect its ability to invest in growth opportunities.
  • Insider ownership is relatively low at 1.20%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent insider sales, including significant transactions by the CEO and a director, could raise concerns about the company's short-term outlook.
  • The stock has experienced volatility, with a beta of 0.32, indicating that it may not respond predictably to market movements.
  • Despite positive analyst ratings, the company operates in a competitive biopharmaceutical market, which could impact its market share and profitability.

ALNY Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $421.28, with a high forecast of $583.00 and a low forecast of $220.00.

27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 23 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALNY shares.

According to analysts, Alnylam Pharmaceuticals's stock has a predicted downside of -9.57% based on their 12-month stock forecasts.

Over the previous 90 days, Alnylam Pharmaceuticals's stock had 2 upgrades by analysts.

Analysts like Alnylam Pharmaceuticals more than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.85 while the average consensus rating score for "medical" companies is 2.78. Learn more on how ALNY compares to other companies.


This page (NASDAQ:ALNY) was last updated on 9/13/2025 by MarketBeat.com Staff
From Our Partners